216 related articles for article (PubMed ID: 3033946)
1. Natural killer cells and tumor immunity: 1985.
Herberman RB
Year Immunol; 1986; 2():254-60. PubMed ID: 3033946
[No Abstract] [Full Text] [Related]
2. In vivo generation, enhancement and recruitment of host cellular immune responses against tumor: influence of MHC antigen expression on clones of tumor cell variants.
Fernández-Cruz E; Pérez M; Zabay JM; Garrido F
Prog Clin Biol Res; 1987; 244():115-25. PubMed ID: 2958867
[No Abstract] [Full Text] [Related]
3. Studies on lymphokine activated killer cells in the rat: analysis of precursor and effector cell phenotype and relationship to natural killer cells.
Hiserodt JC; Vujanovic NL; Reynolds CW; Herberman RB; Cramer DV
Prog Clin Biol Res; 1987; 244():137-46. PubMed ID: 2958869
[No Abstract] [Full Text] [Related]
4. NK cells suppress the generation of Lyt-2+ cytolytic T cells by suppressing or eliminating dendritic cells.
Gilbertson SM; Shah PD; Rowley DA
J Immunol; 1986 May; 136(10):3567-71. PubMed ID: 2871105
[TBL] [Abstract][Full Text] [Related]
5. Enrichment of antitumor effector cells that are effective in vivo from spleen cells of tumor-bearing mice through the use of Dolichos biflorus lectin.
Okada T; Ezawa K; Imai Y; Osawa T
Cancer Res; 1986 Nov; 46(11):5611-7. PubMed ID: 3093067
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes: evidence for specific immune reactions against growing cancers in mice and humans.
Topalian SL; Rosenberg SA
Important Adv Oncol; 1990; ():19-41. PubMed ID: 2182519
[No Abstract] [Full Text] [Related]
7. Human and mouse "LAK" cells expanded in long-term cultures: in vitro and in vivo studies.
Kedar E; Zeira E; Lebendiker Z; Weiss DW; Katan R; Shouval D
Prog Clin Biol Res; 1987; 244():59-75. PubMed ID: 3498959
[No Abstract] [Full Text] [Related]
8. Natural killer cells and tumor immunity: 1987.
Hiserodt JC; Herberman RB
Year Immunol; 1989; 4():201-7. PubMed ID: 2648702
[No Abstract] [Full Text] [Related]
9. Natural cytotoxic activity in murine and human systems. A review.
Lattime EC
Year Immunol; 1986; 2():261-6. PubMed ID: 3554823
[No Abstract] [Full Text] [Related]
10. [Types of cellular antitumor cytotoxicity].
Lomakin MS; Maĭskiĭ IN
Vopr Onkol; 1988; 34(12):1422-32. PubMed ID: 2975420
[No Abstract] [Full Text] [Related]
11. The T cell receptor/T3 complex.
Terhorst C; de Vries J; Georgopoulos K; Gold D; Oettgen H; Pettey C; Spits H; Ucker D; van den Elsen P; Wileman T
Year Immunol; 1986; 2():245-53. PubMed ID: 2437726
[No Abstract] [Full Text] [Related]
12. Inhibitory effects of alloimmune T cells on the generation of cytolytic responses of lymphokine-activated killer cells.
Sugarbaker PH; Matthews W; Steller EP; Eggermont AM
J Biol Response Mod; 1987 Aug; 6(4):430-45. PubMed ID: 3498012
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
14. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.
Hefeneider SH; Conlon PJ; Henney CS; Gillis S
J Immunol; 1983 Jan; 130(1):222-7. PubMed ID: 6600178
[TBL] [Abstract][Full Text] [Related]
15. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
16. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
[No Abstract] [Full Text] [Related]
17. Cell-mediated immunity.
Goust JM
Immunol Ser; 1990; 50():195-215. PubMed ID: 2151118
[No Abstract] [Full Text] [Related]
18. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
19. An ovalbumin peptide-specific cytotoxic T cell clone with antigen self-presentation capacity uses two distinct mechanisms to kill target cells.
Dick T; Reichmann G; Ebnet K; Simon MM; Dienes HP; Echternacher B; Krammer PH; Reske-Kunz AB
Cell Immunol; 1993 Dec; 152(2):333-47. PubMed ID: 8258142
[TBL] [Abstract][Full Text] [Related]
20. Analysis of lymphokine-activated killer (LAK) cells.
Ortaldo JR
Prog Clin Biol Res; 1987; 244():197-206. PubMed ID: 2443928
[No Abstract] [Full Text] [Related]
[Next] [New Search]
